BRCA2 loss‐of‐function germline mutations are associated with esophageal squamous cell carcinoma risk in Chinese
Open Access
- 9 August 2019
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 146 (4) , 1042-1051
Abstract
Esophageal squamous cell carcinoma (ESCC) occurs with highest frequency in China with over 90% mortality, highlighting the need for early detection and improved treatment strategies. We aimed to identify ESCC cancer predisposition gene(s). Our study included 4,517 individuals. The discovery phase using whole‐exome sequencing (WES) included 186 familial ESCC patients from high‐risk China. Targeted gene sequencing validation of 598 genes included 3,289 Henan and 1,228 moderate‐risk Hong Kong Chinese. A WES approach identified BRCA2 loss‐of‐function (LOF) mutations in 3.23% (6/186) familial ESCC patients compared to 0.21% (9/4300) in the ExAC East Asians (odds ratio [OR] = 15.89, p = 2.48 × 10−10). BRCA2 LOF mutation frequency in the combined Henan cohort has significantly higher prevalence (OR = 10.55, p = 0.0035). Results were independently validated in an ESCC Hong Kong cohort (OR = 10.64, p = 0.022). One Hong Kong pedigree was identified to carry a BRCA2 LOF mutation. BRCA2 inactivation in ESCC was via germline LOF mutations and wild‐type somatic allelic loss via loss of heterozygosity. Gene‐based association analysis, including LOF mutations and rare deleterious missense variants defined with combined annotation dependent depletion score ≥30, confirmed the genetic predisposition role of BRCA2 (OR = 9.50, p = 3.44 × 10−5), and provided new evidence for potential association of ESCC risk with DNA repair genes (POLQ and MSH2), inflammation (TTC39B) and angiogenesis (KDR). Our findings are the first to provide compelling evidence of the role of BRCA2 in ESCC genetic susceptibility in Chinese, suggesting defective homologous recombination is an underlying cause in ESCC pathogenesis, which is amenable to therapeutic options based on synthetic lethality approaches such as targeting BRCA2 with PARP1 inhibitors in ESCC.Keywords
Funding Information
- National Natural Science Foundation of China (81872032, U1804262)
This publication has 45 references indexed in Scilit:
- A framework for variation discovery and genotyping using next-generation DNA sequencing dataNature Genetics, 2011
- Mutations in Fanconi anemia genes and the risk of esophageal cancerHuman Genetics, 2011
- Rare, evolutionarily unlikely missense substitutions in CHEK2contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening studyBreast Cancer Research, 2011
- The ECM protein LTBP‐2 is a suppressor of esophageal squamous cell carcinoma tumor formation but higher tumor expression associates with poor patient outcomeInternational Journal of Cancer, 2010
- Extracellular ProteaseADAMTS9Suppresses Esophageal and Nasopharyngeal Carcinoma Tumor Formation by Inhibiting AngiogenesisCancer Research, 2010
- Genetic Heterogeneity of Oesophageal Cancer in High-Incidence Areas of Southern and Northern ChinaPLOS ONE, 2010
- Clinical and pathological characteristics of Chinese patients with BRCA related breast cancerThe HUGO Journal, 2009
- mtDNA evidence: Genetic background associated with related populations at high risk for esophageal cancer between Chaoshan and Taihang Mountain areas in ChinaGenomics, 2007
- Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2Science, 2003
- Identification of the breast cancer susceptibility gene BRCA2Nature, 1995